Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.B.Burgin,
O.T.Magnusson,
J.Singh,
P.Witte,
B.L.Staker,
J.M.Bjornsson,
M.Thorsteinsdottir,
S.Hrafnsdottir,
T.Hagen,
A.S.Kiselyov,
L.J.Stewart,
and
M.E.Gurney
(2010).
Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.
|
| |
Nat Biotechnol, 28,
63-70.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.Barren,
L.Gakhar,
H.Muradov,
K.K.Boyd,
S.Ramaswamy,
and
N.O.Artemyev
(2009).
Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.
|
| |
EMBO J, 28,
3613-3622.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Sato,
Y.Hashiguchi,
and
M.Nishida
(2009).
Evolution of multiple phosphodiesterase isoforms in stickleback involved in cAMP signal transduction pathway.
|
| |
BMC Syst Biol, 3,
23.
|
 |
|
|
|
|
 |
C.C.Heikaus,
J.R.Stout,
M.R.Sekharan,
C.M.Eakin,
P.Rajagopal,
P.S.Brzovic,
J.A.Beavo,
and
R.E.Klevit
(2008).
Solution structure of the cGMP binding GAF domain from phosphodiesterase 5: insights into nucleotide specificity, dimerization, and cGMP-dependent conformational change.
|
| |
J Biol Chem, 283,
22749-22759.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Spina
(2008).
PDE4 inhibitors: current status.
|
| |
Br J Pharmacol, 155,
308-315.
|
 |
|
|
|
|
 |
S.K.Field
(2008).
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.
|
| |
Expert Opin Investig Drugs, 17,
811-818.
|
 |
|
|
|
|
 |
X.J.Zhang,
K.B.Cahill,
A.Elfenbein,
V.Y.Arshavsky,
and
R.H.Cote
(2008).
Direct Allosteric Regulation between the GAF Domain and Catalytic Domain of Photoreceptor Phosphodiesterase PDE6.
|
| |
J Biol Chem, 283,
29699-29705.
|
 |
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
and
C.G.Zhan
(2008).
Dynamic structures of phosphodiesterase-5 active site by combined molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
J Comput Chem, 29,
1259-1267.
|
 |
|
|
|
|
 |
M.Conti,
and
J.Beavo
(2007).
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.
|
| |
Annu Rev Biochem, 76,
481-511.
|
 |
|
|
|
|
 |
W.M.Brown
(2007).
Treating COPD with PDE 4 inhibitors.
|
| |
Int J Chron Obstruct Pulmon Dis, 2,
517-533.
|
 |
|
|
|
|
 |
A.Ghavami,
W.D.Hirst,
and
T.J.Novak
(2006).
Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?
|
| |
Drugs R D, 7,
63-71.
|
 |
|
|
|
|
 |
A.Johner,
S.Kunz,
M.Linder,
Y.Shakur,
and
T.Seebeck
(2006).
Cyclic nucleotide specific phosphodiesterases of Leishmania major.
|
| |
BMC Microbiol, 6,
25.
|
 |
|
|
|
|
 |
D.Wang,
and
X.Cui
(2006).
Evaluation of PDE4 inhibition for COPD.
|
| |
Int J Chron Obstruct Pulmon Dis, 1,
373-379.
|
 |
|
|
|
|
 |
F.S.Menniti,
W.S.Faraci,
and
C.J.Schmidt
(2006).
Phosphodiesterases in the CNS: targets for drug development.
|
| |
Nat Rev Drug Discov, 5,
660-670.
|
 |
|
|
|
|
 |
H.Park,
J.Lee,
and
S.Lee
(2006).
Critical assessment of the automated AutoDock as a new docking tool for virtual screening.
|
| |
Proteins, 65,
549-554.
|
 |
|
|
|
|
 |
Y.Xiong,
H.T.Lu,
Y.Li,
G.F.Yang,
and
C.G.Zhan
(2006).
Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.
|
| |
Biophys J, 91,
1858-1867.
|
 |
|
|
|
|
 |
G.L.Card,
L.Blasdel,
B.P.England,
C.Zhang,
Y.Suzuki,
S.Gillette,
D.Fong,
P.N.Ibrahim,
D.R.Artis,
G.Bollag,
M.V.Milburn,
S.H.Kim,
J.Schlessinger,
and
K.Y.Zhang
(2005).
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
|
| |
Nat Biotechnol, 23,
201-207.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Wang,
Y.Liu,
Y.Chen,
H.Robinson,
and
H.Ke
(2005).
Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
|
| |
J Biol Chem, 280,
30949-30955.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Y.Zhang,
P.N.Ibrahim,
S.Gillette,
and
G.Bollag
(2005).
Phosphodiesterase-4 as a potential drug target.
|
| |
Expert Opin Ther Targets, 9,
1283-1305.
|
 |
|
|
|
|
 |
S.Kunz,
M.Oberholzer,
and
T.Seebeck
(2005).
A FYVE-containing unusual cyclic nucleotide phosphodiesterase from Trypanosoma cruzi.
|
| |
FEBS J, 272,
6412-6422.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|